首页> 外文期刊>Diagnostic microbiology and infectious disease >Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis
【24h】

Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis

机译:血清ProCalcitonin和C反应蛋白水平作为肝硬化患者细菌感染的标志:系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

The diagnostic value of procalcitonin (PCT) for patients with liver cirrhosis is unclear. We searched the PubMed, EMBASE, and Cochrane databases for studies published through December 2013 that evaluated the diagnostic performance of PCT for patients with acute or chronic liver disease with suspected systemic infection. We summarized the test performance characteristics by using forest plots, hierarchical summary receiver operating characteristic curves, and bivariate random effects models. Our search identified 230 citations, of which 10 diagnostic studies that evaluated 1144 patients and 435 bacterial infection episodes (32.1%) were ultimately included for analysis. The bivariate pooled sensitivity estimates were 79% (95% confidence interval [CI]: 64%-89%) for PCT tests and 77% (95% CI: 69%-84%) for C-reactive protein (CRP) tests. Pooled specificity estimates were higher for both PCT and CRP tests (PCT, 89% [95% CI: 82%-94%]; CRP, 85% [95% CI: 76%-90%]). The positive likelihood ratio for PCT (LR+, 7.38,95% CI: 4.70-11.58) was sufficiently high to qualify PCT as a rule-in diagnostic tool, and the negative likelihood ratio for CRP was sufficiently low to qualify CRP as an acceptable rule-out diagnostic tool (LR- 023, 95% Cl: 0.13-0.41) in patients with no signs of infection. Available clinical evidence showed that PCT has comparable accuracy to CRP for the diagnosis of systemic infection in patients with liver cirrhosis. Compared with patients with normal liver function, both PCT and CRP tests have acceptable accuracy for diagnosing bacterial infection among patients with liver cirrhosis. (C) 2014 Elsevier Inc. All rights reserved.
机译:对肝硬化患者的ProCalcitonin(PCT)的诊断价尚不清楚。我们搜索了PubMed,Embase和Cochrane数据库,用于2013年12月出版的研究,评估了PCT对急性或慢性肝病患者进行疑似全身感染的诊断性能。我们通过使用森林图,分层摘要接收器操作特征曲线和双变量随机效果模型来总结测试性能特征。我们的搜索确定了230个引文,其中10个诊断研究,评估了1144名患者和435例细菌感染事件(32.1%)的分析。 PCT试验的二抗体汇集估计值为79%(95%置信区间:64%-89%),C反应蛋白(CRP)试验77%(95%CI:69%-84%)。 PCT和CRP试验的汇集特异性估算较高(PCT,89%[95%CI:82%-94%]; CRP,85%[95%CI:76%-90%])。 PCT(LR +,7.38,95%CI:4.70-11.58)的阳性似然比足够高,以鉴定PCT作为规则诊断工具,CRP的负似然比足够低,以使CRP作为可接受的规则患者诊断工具(LR-023,95%CL:0.13-0.41)没有感染迹象。可用的临床证据表明,PCT对肝硬化患者诊断系统感染的CRP具有相当的准确性。与具有正常肝功能的患者相比,PCT和CRP测试都具有可接受的准确性,可诊断肝硬化患者的细菌感染。 (c)2014年elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号